Quanterix’ Simoa® Technology Powers Latest Breakthrough in Epstein-Barr Virus and Multiple Sclerosis
Retrieved on:
Wednesday, January 26, 2022
Oncology, Health, Infectious Diseases, Other Health, Research, Science, Cardiology, Serum, Infection, Seroconversion, Rheumatology, Treatment, Roman Hrusovsky, Cytomegalovirus, Research, Quality of life, Patient, Epstein–Barr virus, EBV, Private Securities Litigation Reform Act, News, Association, Population, European Committee on Radiation Risk, Public health, Risk, Blood, Virus, Multiple sclerosis, Prevalence, Molecular mimicry, Cardiology, AFL, Diagnosis, Minuteman Library Network, Corporation, NASDAQ, Harvard University, Plasma, Harvard T.H. Chan School of Public Health, Congress, Technology, Neurology, Nature, National, Longevity, MS, Inflammation, EBNA1, Disease, Forward-looking statement, U.S. Securities and Exchange Commission, CNS, PPH, Founder, Pharmaceutical industry, Medical imaging, Online shopping, Science
Their analysis produced evidence that EBV increases susceptibility toward developing MS and supports the virus association with the pathogenesis of MS.
Key Points:
- Their analysis produced evidence that EBV increases susceptibility toward developing MS and supports the virus association with the pathogenesis of MS.
- Part of what makes MS so devastating is that it often goes unrecognized for years or is mistaken for other neurological conditions.
- Quanterix technology recently supported 31 scientific presentations at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the worlds largest meeting dedicated to advancing research for MS.
- The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.